Gamida Cell Ltd's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Gamida Cell Ltd (GMDA) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Gamida Cell Ltd vs Its Competitors
- Profitability: Its 2,241.1% net margin compares with -96.3% for the peer group.
- Peer revenue share: Gamida Cell Ltd accounted for 0.0% of combined revenue among its tracked peer group.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
GMDA Sales vs. its Competitors, Q1 2024
With a net margin of 2,241.12 %, Gamida Cell Ltd achieved higher profitability than its competitors (-96.27 %).
Gamida Cell Ltd generated 0.00 % of the combined sales of its peer group.
Gamida Cell Ltd vs. its Competitors, Q1 2024
Net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Gamida Cell Ltd and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Gamida Cell Ltd | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (2) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Gamida Cell Ltd's competitor groups requires a Commercial License.
Gamida Cell Ltd's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Gamida Cell Ltd | - | - | - | Yes |
| Competitors combined (31) | ||||
| High-Confidence Competitors (2) | - | - |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
GMDA Stock Performance relative to its Competitors
GMDA Stock Performance relative to High-Confidence Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Moderna Inc | 282.9% | Outperformed |
| 2 | Iovance Biotherapeutics inc | 282.9% | Outperformed |
| 3 | Revolution Medicines Inc | 282.9% | Outperformed |
| 4 | Immunitybio inc | 282.9% | Outperformed |
| 5 | Fate Therapeutics Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Gamida Cell Ltd's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Publicly Traded Peers of Gamida Cell Ltd
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Gamida Cell Ltd | 6.11 | - |
| Gilead Sciences Inc | 184,933.54 | 30,457.00 |
| Bristol myers Squibb Company | 128,020.48 | 49,186.00 |
| Moderna Inc | 76,734.40 | 2,228.00 |
| Revolution Medicines Inc | 43,787.84 | 29.51 |
| Seagen Inc | 43,034.00 | 2,300.35 |
| SUBTOTAL | 509,826.99 | 86,236.73 |
Sign in to see all competitors of Gamida Cell Ltd .
Sources: Gamida Cell Ltd's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Gamida Cell Ltd versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Gamida Cell Ltd's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Allogene Therapeutics Inc | Named by the company | 85% |
| Quoin Pharmaceuticals Ltd | Named by the company | 85% |
| Garuda Therapeutics | Named by the company | 85% |
| Immunitybio inc | Named by the company | 85% |
| Celyad Oncology Sa | Named by the company | 85% |
| Fate Therapeutics Inc | Named by the company | 85% |
| Bluebird Bio Inc | Named by the company | 85% |
| Senti Biosciences Holdings Inc | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Gamida Cell Ltd's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.
Gamida Cell Ltd's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Immunitybio inc | Reportable 100.00 % |
| Iovance Biotherapeutics inc | Single reportable segment 100.00 % |
| Novavax inc | Reportable 100.00 % |
| Immunocore Holdings Plc | Reportable 100.00 % |
| Lenz Therapeutics Inc | Reportable 100.00 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Gamida Cell Ltd's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Gamida Cell Ltd | 6 | - | 809,949 |
| Gilead Sciences Inc | 184,934 | 1,791,588 | -190,588 |
| Bristol myers Squibb Company | 128,020 | 1,513,415 | 285,354 |
| Moderna Inc | 76,734 | 474,043 | -670,426 |
| Revolution Medicines Inc | 43,788 | 33,420 | -2,002,588 |
| Seagen Inc | 43,034 | 1,916,959 | -625,187 |
| PEERS TOTAL | 509,821 | 1,398,131 | -36,320 |
Gamida Cell Ltd's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent filing. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Gilead Sciences Inc | United States 70.78 % |
| Bristol myers Squibb Company | United States 67.79 % |
| Immunitybio inc | United States 98.99 % |
| Iovance Biotherapeutics inc | US 98.66 % |
| Novavax inc | United States 68.88 % |
Source: revenue geography as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Gamida Cell Ltd's Valuation vs Competitive Position
Valuation multiples vs the Biotechnology & Pharmaceuticals industry average (95 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Biotechnology & Pharmaceuticals industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | 0.5x | 26.7x | -26.3x |
| EV / EBITDA | 3.5x | 21.3x | -17.8x |
| P/B | -3.4x | 5.1x | -8.5x |
| Return on Equity | - | industry aggregate | - |
| Return on Invested Capital | 183.14 % | -5.98 % (avg) | 189.12 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Gamida Cell Ltd's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
No rule matched.
Weaknesses
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
- Industry revenue growing at a healthy 10.0% median pace.
- Trades at a lower P/E than the industry average (0.5x vs 26.7x) despite a higher return on invested capital -- a possible re-rating opportunity.
- A meaningful share of tracked competitors (45.20 %) show financial-distress signals, a possible opening to gain share.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-9.6% annualized).
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Gamida Cell Ltd's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Gamida Cell Ltd | 1.80 | 1.33 | - |
| Gilead Sciences Inc | - | 1.54 | 1.27 |
| Bristol myers Squibb Company | 0.49 | 1.35 | 2.31 |
| Moderna Inc | 0.86 | 2.88 | 0.07 |
| Revolution Medicines Inc | 1.35 | 7.28 | 0.07 |
| Seagen Inc | 0.43 | 3.22 | - |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Gamida Cell Ltd's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Gamida Cell Ltd | Q1 2024 | - | - |
| Gilead Sciences Inc | Q2 2026 | +10.2 % | - |
| Bristol myers Squibb Company | Q2 2026 | +5.7 % | +152.6 % |
| Moderna Inc | Q2 2026 | +2.1 % | - |
| Revolution Medicines Inc | Q2 2026 | - | - |
| Seagen Inc | Q3 2023 | +27.1 % | - |
| PEERS TOTAL | +8.7 % | - |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Gamida Cell Ltd's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Gamida Cell Ltd | Q1 2024 | - | -89.2 % |
| Gilead Sciences Inc | Q2 2026 | +5.2 % | +30.8 % |
| Bristol myers Squibb Company | Q2 2026 | +10.5 % | -15.5 % |
| Moderna Inc | Q2 2026 | -21.8 % | +1,133.3 % |
| Revolution Medicines Inc | Q2 2026 | - | -69.3 % |
| Seagen Inc | Q3 2023 | +52.8 % | +175.7 % |
Gamida Cell Ltd's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Gamida Cell Ltd | 77.06% | 120.18% | - |
| Gilead Sciences Inc | - | - | - |
| Bristol myers Squibb Company | 10.27% | 13.58% | 46.65% |
| Moderna Inc | - | - | - |
| Revolution Medicines Inc | - | - | - |
| Seagen Inc | - | - | - |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Gamida Cell Ltd's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Gamida Cell Ltd | 0.07 | - |
| Gilead Sciences Inc | - | 6.07 |
| Bristol myers Squibb Company | 13.76 | 2.60 |
| Moderna Inc | - | 34.44 |
| Revolution Medicines Inc | - | 1,483.83 |
| Seagen Inc | - | 18.71 |
| PEERS AVERAGE | - | 5.91 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.